The purpose of this study is to find the highest dose of an investigational drug called KPT-330 that can be given safely in patients with advanced or metastatic solid tumors that persist or have returned after standard therapy, or for which no standard therapy exists. KPT-330 works by blocking the movement of proteins that cancer cells use to escape the natural control mechanisms in the body that normally inhibit cancer growth.
In order for a cancer cell to grow, there are certain proteins that need to be shuttled from the center of the cell (nucleus) to the cytoplasm (the fluid surrounding the nucleus). KPT-330 works by trapping those proteins inside the nucleus, where they can no longer function to keep the cancer cell alive or promote its growth. KPT-330 is a pill that is taken orally (by mouth).